Cardiac Toxicity of 5-Fluorouracil: A Study on 1083 Patients
Open Access
- 1 December 1982
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 68 (6) , 505-510
- https://doi.org/10.1177/030089168206800609
Abstract
The possible onset of cardiotoxic manifestations during chemotherapy with 5-fluorouracil (5-FU) was evaluaetd in 1083 patients treated with the drug for various kinds of neoplasm. We recognized 17 cases of 5-FU cardiopathy (usually anginous crises but also myocardial infarction). The comprehensive incidence was 1.6 %, with a significantly greater risk (4.5 % vs 1.1 %) for patients with a positive anamnesis of previous cardiopathy. On the contrary, age and combination with other antiblastic drugs had no affect on the appearance of cardiopathy. We conclude that 5-FU cardiopathy, although rare, has to be taken into account in oncologic practice, chiefly in those patients already affected with cardiac diseases.This publication has 10 references indexed in Scilit:
- Cardiotoxicity of 5-FluorouracilTumori Journal, 1980
- Cardiac Toxicity from Antitumor TherapyOncology, 1980
- 5-Fuorouracil CardiotoxicityTumori Journal, 1979
- Fluorouracil cardiotoxicity.BMJ, 1978
- Fluorouracil cardiotoxicity.BMJ, 1978
- Fluorouracil cardiotoxicity.BMJ, 1978
- Cardiotoxic effects of antitumor agentsCancer Chemotherapy and Pharmacology, 1978
- CARDIOTOXICITY OF 5-FLUOROURACILThe Lancet, 1977
- 5-FLUOROURACIL AND ANGINAThe Lancet, 1975
- Safety of medicines.BMJ, 1972